Researchers have developed a new platform called Lucis that leverages artificial intelligence to monitor health through blood biomarker data. This Paris-based startup has attracted significant investment, raising $20 million to expand its services, which aim to provide proactive health tracking before traditional healthcare systems intervene. Lucis allows users to track over 110 biomarkers related to metabolic health, cardiovascular risk, inflammation, and hormone levels, offering tailored lifestyle recommendations based on their individual medical histories.

This approach is particularly relevant for anyone looking to age well and maintain their health. With 75% of users improving at least three key biomarkers through lifestyle changes, Lucis demonstrates the potential for proactive health management. The platform has already attracted 10,000 users across Europe, highlighting a growing interest in preventive health strategies. By identifying sub-clinical risks early—before they develop into chronic conditions—people can take actionable steps to improve their overall well-being.

Currently, the platform is still in its early stages, having launched just last year. While it has shown promising results, the evidence is based on a small cohort of users rather than large-scale clinical trials. Users have reported an impressive 80% retest rate, indicating ongoing engagement with the platform. However, it’s important to remember that fluctuations in biomarkers can vary and should not be interpreted as definitive diagnoses. Lucis aims to combine AI-driven insights with physician oversight, ensuring that users receive clinically relevant guidance.

As preventive health becomes more integrated into European healthcare, platforms like Lucis may reshape how people approach their health. Engaging with such technologies could empower individuals to take charge of their health and potentially extend their longevity.

Source: longevity.technology